Associations of resistin with inflammation and insulin resistance in patients with type 2 diabetes mellitus

References

• Steppan C. M., Bailey S. T., Bhat S., Brown E. J., Banerjee R. R., Wright C. M., et al. The hormone resistin links obesity to diabetes. Nature 2001; 409: 307–12
   PubMed Web of Science ®Google Scholar
• Steppan C. M., Lazar M. A. Resistin and obesity‐associated insulin resistance. Trends Endocrinol Metab 2002; 13: 18–23
   PubMed Web of Science ®Google Scholar
• Steppan C. M., Brown E. J., Wright C. M., Bhat S., Banerjee R. R., Dai C. Y., et al. A family of tissue‐specific resistin‐like molecules. Proc Natl Acad Sci USA 2001; 98: 502–6
   PubMed Web of Science ®Google Scholar
• Way J. M., Gorgun C. Z., Tong Q., Uysal K. T., Brown K. K., Harrington W. W., et al. Adipose tissue resistin expression is severely suppressed in obesity and stimulated by peroxisome proliferator‐activated receptor gamma agonists. J Biol Chem 2001; 276: 25651–3
   PubMed Web of Science ®Google Scholar
• Le Lay S., Boucher J., Rey A., Castan‐Laurell I., Krief S., Ferre P., et al. Decreased resistin expression in mice with different sensitivities to a high‐fat diet. Biochem Biophys Res Commun 2001; 289: 564–7
   PubMedGoogle Scholar
• Juan C. C., Au L. C., Fang V. S., Kang S. F., Ko Y. H., Kuo S. F., et al. Suppressed gene expression of adipocyte resistin in an insulin‐resistant rat model probably by elevated free fatty acids. Biochem Biophys Res Commun 2001; 289: 1328–33
   PubMedGoogle Scholar
• Masuzaki H., Paterson J., Shinyama H., Morton N., Mullins J., Seckl J., et al. A transgenic model of visceral obesity and the metabolic syndrome. Science 2001; 294: 2166–70
   PubMed Web of Science ®Google Scholar
• Milan G., Granzotto M., Scarda A., Calcagno A., Pagano C., Federspil G., et al. Resistin and adiponectin expression in visceral fat of obese rats: effect of weight loss. Obes Res 2002; 10: 1095–103
   PubMedGoogle Scholar
• Heilbronn L. K., Rood J., Janderova L., Albu J. B., Kelley D. E., Ravussin E., et al. Relationship between serum resistin concentrations and insulin resistance in nonobese, obese, and obese diabetic subjects. J Clin Endocrinol Metab 2004; 89: 1844–8
   PubMed Web of Science ®Google Scholar
• Abdella N., Al Arouj M., Al Nakhi A., Al Assoussi A., Moussa M. Non‐insulin‐dependent diabetes in Kuwait: prevalence rates and associated risk factors. Diabetes Res Clin Pract 1998; 42: 187–96
   PubMed Web of Science ®Google Scholar
• Abdella N. A., Mojiminiyi O. A., Moussa M. A., Zaki M., Al Mohammedi H., Al Ozairi E. S., et al. Plasma leptin concentration in patients with type 2 diabetes: relationship to cardiovascular disease risk factors and insulin resistance. Diabet Med 2005; 22: 278–85
   PubMedGoogle Scholar
• Holcomb I. N., Kabakoff R. C., Chan B., Baker T. W., Gurney A., Henzel W., et al. FIZZ1, a novel cysteine‐rich secreted protein associated with pulmonary inflammation, defines a new gene family. EMBO J 2000; 19: 4046–55
   PubMed Web of Science ®Google Scholar
• Reilly M. P., Lehrke M., Wolfe M. L., Rohatgi A., Lazar M. A., Rader D. J. Resistin is an inflammatory marker of atherosclerosis in humans. Circulation 2005; 111: 932–9
   PubMed Web of Science ®Google Scholar
• Alberti K. G., Zimmet P. Z. Definition, diagnosis and classification of diabetes mellitus and its complications: diagnosis and classification of diabetes mellitus: provisional report of a WHO consultation. Diabet Med 1998; 15: 539–53
   PubMed Web of Science ®Google Scholar
• Mojiminiyi O. A., Abdella N. A., Al Arouj M., Ben Nakhi A. Adiponectin, insulin resistance and clinical expression of the metabolic syndrome in patients with type 2 diabetes. Int J Obes. 2006, Epub ahead of print
   Google Scholar
• Chobanian A. V., Bakris G. L., Black H. R., Cushman W. C., Green L. A., Izzo J. L, Jr., et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report. JAMA 2003; 289: 2560–71
   PubMed Web of Science ®Google Scholar
• Blackburn H. Electrocardiographic classification for population comparisons. The Minnesota code. J Electrocardiol 1969; 52: 5–9
   Google Scholar
• Rose G. A. The diagnosis of ”ischaemic” heart pain and intermittent claudication in field surveys. Bull World Health Org 1962; 27: 645–58
   PubMed Web of Science ®Google Scholar
• Diabetes Trials Unit, Oxford, URL. HOMA Calculator v2.2: http://www.dtu.ox.ac.uk/index.html? (maindoc = /publications/accessed April 4 2005)
   Google Scholar
• Balkau B., Charles M. The European Group for the Study of Insulin Resistance (EGIR). Comment on the provisional report from the WHO consultation. Diabet Med 1999; 16: 442–3
   PubMed Web of Science ®Google Scholar
• Mojiminiyi O. A., Abdella N., Moussa M. A., Akanji A. O., Al Mohammedi H., Zaki M. Association of C‐reactive protein with coronary heart disease risk factors in patients with type 2 diabetes mellitus. Diabetes Res Clin Pract 2002; 58: 37–44
   PubMed Web of Science ®Google Scholar
• Friedewald W. T., Levy R. T., Fredrickson D. S. Estimation of the concentration of low density lipoprotein cholesterol in plasma without use of the ultracentrifuge. Clin Chem 1972; 18: 449–52
   PubMed Web of Science ®Google Scholar
• Mojiminiyi O. A., Abdella N. Evaluation of cystatin C and beta‐2 microglobulin as markers of renal function in patients with type 2 diabetes mellitus. J Diabetes Complications 2003; 17: 160–8
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Standards of medical care in diabetes diabetes care. 28. S4–36
   Google Scholar
• Pearson T., Mensah G., Alexander R., Anderson J., Cannon R., Criqui M. Markers of inflammation and cardiovascular disease: application to clinical and public health practice. A statement for healthcare professionals from the centers for disease control and prevention and the American Heart Association. Circulation 2003; 107: 499–11
   PubMed Web of Science ®Google Scholar
• Patel L., Buckels A. C., Kinghorn I. J., Murdock P. R., Holbrook J. D., Plumpton C., et al. Resistin is expressed in human macrophages and directly regulated by PPAR gamma activators. Biochem Biophys Res Commun 2003; 300: 472–6
   PubMed Web of Science ®Google Scholar
• Perfetto F., Manuso F., Tarquini R. Leukocytosis and hyperleptinemia in obesity: is there a link. Haematologica 2002; 87: ELT25
   PubMedGoogle Scholar
• Savage D. B., Sewter C. P., Klenk E. S., Segal D. G., Vidal‐Puig A., Considine R. V., et al. Resistin/Fizz3 expression in relation to obesity and peroxisome proliferator‐activated receptor‐gamma action in humans. Diabetes 2001; 50: 2199–202
   PubMed Web of Science ®Google Scholar
• van Dielen F. M., van't Veer C., Schols A. M., Soeters P. B., Buurman W. A., Greve J. W. Increased leptin concentrations correlate with increased concentrations of inflammatory markers in morbidly obese individuals. Int J Obes Relat Metab Disord 2001; 25: 1759–66
   PubMed Web of Science ®Google Scholar
• Yudkin J. S., Stehouwer C. D., Emeis J. J., Coppack S. W. C‐reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue?. Arterioscler Thromb Vasc Biol 1999; 19: 972–8
   PubMed Web of Science ®Google Scholar
• Festa A., D'Agostino R., Howard G., Mykkanen L., Tracy R. P., Haffner S. M. Chronic subclinical inflammation as part of the insulin resistance syndrome: The Insulin Resistance Atherosclerosis Study (IRAS). Circulation 2000; 102: 42–7
   PubMed Web of Science ®Google Scholar
• Youd J. M., Rattigan S., Clark M. G. Acute impairment of insulin‐mediated capillary recruitment and glucose uptake in rat skeletal muscle in vivo by TNF‐(alpha). Diabetes 2000; 49: 1904–9
   PubMed Web of Science ®Google Scholar
• Lehrke M., Reilly M. P., Millington S. C., Iqbal N., Rader D. J., Lazar M. A. An inflammatory cascade leading to hyperresistinemia in humans. PLos Med 2004; 1: e45
   PubMed Web of Science ®Google Scholar
• Bokarewa M., Nagaev I., Dahlberg L., Smith U., Tarkowski A. Resistin, an adipokine with potent proinflammatory properties. J Immunol 2005; 174: 5789–95
   PubMed Web of Science ®Google Scholar
• Gomez‐Ambrosi J., Fruhbeck G. Do resistin and resistin‐like molecules also link obesity to inflammatory diseases?. Ann Intern Med 2001; 135: 306–7
   PubMedGoogle Scholar
• Kaser S., Kaser A., Sandhofer A., Ebenbichler C. F., Tilg H., Patsch J. R. Resistin messenger‐RNA expression is increased by proinflammatory cytokines in vitro. Biochem Biophys Res Commun 2003; 309: 286–90
   PubMed Web of Science ®Google Scholar
• Kielstein J. T., Becker B., Graf S., Brabant G., Haller H., Fliser D. Increased resistin blood levels are not associated with insulin resistance in patients with renal disease. Am J Kidney Dis 2003; 42: 62–6
   PubMedGoogle Scholar
• Diez J. J., Iglesias P., Fernandez‐Reyes M. J., Aguilera A., Bajo M. A., Alvarez‐Fidalgo P., et al. Serum concentrations of leptin, adiponectin and resistin, and their relationship with cardiovascular disease in patients with end‐stage renal disease. Clin Endocrinol 2005; 62: 242–9
   PubMed Web of Science ®Google Scholar
• Vozarova de Courten B., Degawa‐Yamauchi M., Considine R. V., Tataranni P. A. High serum resistin is associated with an increase in adiposity but not a worsening of insulin resistance in Pima Indians. Diabetes 2004; 53: 1279–84
   PubMedGoogle Scholar
• Burnett M. S., Devaney J. M., Adenika R. J., Lindsay R., Howard B. V. Cross‐sectional associations of resistin, coronary heart disease, and insulin resistance. J Clin Endocrinol Metab 2006; 91: 64–8
   PubMed Web of Science ®Google Scholar
• Ma X., Warram J. H., Trischitta V., Doria A. Genetic variants at the resistin locus and risk of type 2 diabetes in Caucasians. J Clin Endocrinol Metab 2002; 87: 4407–10
   PubMed Web of Science ®Google Scholar
• Wang H., Chu W. S., Hemphill C., Elbein S. C. Human resistin gene: molecular scanning and evaluation of association with insulin sensitivity and type 2 diabetes in Caucasians. J Clin Endocrinol Metab 2002; 87: 2520–4
   PubMed Web of Science ®Google Scholar
• Duncan B. B., Schmidt M. I., Pankow J. S., Ballantyne C. M., Couper D., Vigo A., et al. Low‐grade systemic inflammation and the development of type 2 diabetes: the Atherosclerosis Risk in Communities Study. Diabetes 2003; 52: 1799–105
   PubMed Web of Science ®Google Scholar
• Hotamisligil G. S. The irresistible biology of resistin. J Clin Invest 2003; 111: 173–4
   PubMedGoogle Scholar